<p>哈伯资本顾问公司在最近向证券交易委员会（SEC）披露的文件中表示，在第三季度将其在海默尼克斯公司（NYSE:HAE - 免费报告）的持股比例提高了 49.7%。该基金在本季度额外购买了 14,226 股后，持有该医疗仪器供应商的 42,859 股股票。哈伯资本顾问公司在最近的报告期末拥有海默尼克斯 0.09% 的股份，价值 2,089,000 美元。</p>
<p>其他几家机构投资者也增加或减少了在 HAE 的持股。Quarry LP 在第一季度将其在海默尼克斯的持股提高了 63.4%。Quarry LP 现在拥有 495 股该医疗仪器供应商的股票，价值 31,000 美元，此前在上个季度又购买了 192 股。EverSource Wealth Advisors LLC 在第二季度将其在海默尼克斯的持股提高了 2,640.0%。EverSource Wealth Advisors LLC 现在拥有 411 股该医疗仪器供应商的股票，价值 31,000 美元，此前在上个季度又购买了 396 股。GAMMA Investing LLC 在第二季度将其在海默尼克斯的持股提高了 59.4%。GAMMA Investing LLC 现在拥有 443 股该医疗仪器供应商的股票，价值 33,000 美元，此前在上个季度又购买了 165 股。UMB Bank n.a.在第二季度将其在海默尼克斯的持股提高了 91.7%。UMB Bank n.a.现在拥有 669 股该医疗仪器供应商的股票，价值 50,000 美元，此前在上个季度又购买了 320 股。最后，Elevation Point Wealth Partners LLC 在第二季度获得了海默尼克斯的新股份，价值约 64,000 美元。目前 99.67% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级调整</h2>
<p>几位研究分析师对该公司发表了评论。华尔街禅在 12 月 14 日的研究报告中将海默尼克斯的评级从 “买入” 下调至 “持有”。雷蒙德·詹姆斯金融公司在 11 月 14 日的研究报告中重申了 “跑赢大盘” 的评级，并设定了海默尼克斯股票的目标价为 90.00 美元。摩根大通在 12 月 12 日的研究报告中将海默尼克斯的目标价从 62.00 美元提高至 74.00 美元，并给予该公司 “中性” 评级。罗伯特·W·贝尔德在 12 月 15 日的研究报告中将海默尼克斯的目标价从 87.00 美元提高至 99.00 美元，并给予该公司 “跑赢大盘” 评级。最后，瑞穗在 12 月 17 日的报告中将海默尼克斯的目标价从 75.00 美元提高至 90.00 美元，并给予该股票 “跑赢大盘” 评级。两位分析师对该股票给予了强烈买入评级，七位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价为 84.10 美元。</p>
<p><strong>获取我们对海默尼克斯的最新分析</strong></p>
<h2>海默尼克斯股票下跌 0.4%</h2>
<p>海默尼克斯（NYSE:HAE）股票在周五开盘时为 80.01 美元。该公司的 50 日简单移动平均线为 70.87 美元，200 日简单移动平均线为 65.16 美元。该公司的债务与股本比率为 1.08，流动比率为 1.64，速动比率为 1.03。海默尼克斯公司的 1 年最低价为 47.31 美元，1 年最高价为 87.32 美元。该公司的市值为 37.5 亿美元，市盈率为 23.39，市盈率增长比率为 1.51，贝塔值为 0.30。</p>
<p>海默尼克斯（NYSE:HAE - 获取免费报告）最近在 11 月 6 日宣布了其季度财报。这家医疗仪器供应商报告本季度每股收益（EPS）为 1.27 美元，超出市场共识预期的 1.12 美元，超出 0.15 美元。海默尼克斯的净利润率为 12.67%，股本回报率为 27.22%。该公司在本季度的收入为 3.2732 亿美元，而分析师预期为 3.1161 亿美元。在去年同期，该公司的每股收益为 1.12 美元。该公司的收入同比下降了 5.3%。海默尼克斯已将其 2026 财年的指导目标设定为 4.800-5.00 每股收益。研究分析师平均预测海默尼克斯公司本年度将发布 4.55 每股收益。</p>
<h2>海默尼克斯公司简介</h2>
<p>(免费报告)</p>
<p>海默尼克斯公司是一家全球血液管理解决方案提供商，支持血液及血液制品的收集、处理和输血。该公司的产品旨在提高血液中心、医院和血浆收集设施的患者安全性和运营效率。海默尼克斯通过提供集成系统、软件和消耗品，满足全球医疗服务提供者在血液管理全过程中的关键需求。</p>
<p>该公司的产品组合包括自动化血液成分分离和血浆收集系统、外科血液回收和凝血监测设备，以及病原体去除技术。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比海默尼克斯更好</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备开战</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
<li>来自奇怪新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 HAE 股票吗？</strong> 访问 HoldingsChannel.com 获取海默尼克斯公司（NYSE:HAE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1IQUU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1IQUU"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在海默尼克斯吗？</h2>
<p>在考虑海默尼克斯之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Haemonetics 并不在名单上。</p>
<p>虽然 Haemonetics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>哈伯资本顾问公司在第三季度将其在海蒙尼克斯公司的股份增加了 49.7%，目前持有 42,859 股，价值 2,089,000 美元。其他机构投资者也调整了他们的持股。分析师对海蒙尼克斯的评级褒贬不一，平均评级为 “适度买入”，平均目标价为 84.10 美元。海蒙尼克斯报告的季度每股收益为 1.27 美元，超出预期，收入为 3.2732 亿美元。该公司在全球提供血液管理解决方案</p>

<p>Harbor Capital Advisors Inc. boosted its position in Haemonetics Corporation (NYSE:HAE - Free Report) by 49.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,859 shares of the medical instruments supplier's stock after acquiring an additional 14,226 shares during the quarter. Harbor Capital Advisors Inc. owned 0.09% of Haemonetics worth $2,089,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>哈伯资本顾问公司在最近向证券交易委员会（SEC）披露的文件中表示，在第三季度将其在海默尼克斯公司（NYSE:HAE - 免费报告）的持股比例提高了 49.7%。该基金在本季度额外购买了 14,226 股后，持有该医疗仪器供应商的 42,859 股股票。哈伯资本顾问公司在最近的报告期末拥有海默尼克斯 0.09% 的股份，价值 2,089,000 美元。</p>
</div><p>Several other institutional investors have also added to or reduced their stakes in HAE. Quarry LP boosted its holdings in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 396 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after buying an additional 165 shares during the last quarter. UMB Bank n.a. boosted its stake in Haemonetics by 91.7% in the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock valued at $50,000 after buying an additional 320 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Haemonetics in the second quarter valued at about $64,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者也增加或减少了在 HAE 的持股。Quarry LP 在第一季度将其在海默尼克斯的持股提高了 63.4%。Quarry LP 现在拥有 495 股该医疗仪器供应商的股票，价值 31,000 美元，此前在上个季度又购买了 192 股。EverSource Wealth Advisors LLC 在第二季度将其在海默尼克斯的持股提高了 2,640.0%。EverSource Wealth Advisors LLC 现在拥有 411 股该医疗仪器供应商的股票，价值 31,000 美元，此前在上个季度又购买了 396 股。GAMMA Investing LLC 在第二季度将其在海默尼克斯的持股提高了 59.4%。GAMMA Investing LLC 现在拥有 443 股该医疗仪器供应商的股票，价值 33,000 美元，此前在上个季度又购买了 165 股。UMB Bank n.a.在第二季度将其在海默尼克斯的持股提高了 91.7%。UMB Bank n.a.现在拥有 669 股该医疗仪器供应商的股票，价值 50,000 美元，此前在上个季度又购买了 320 股。最后，Elevation Point Wealth Partners LLC 在第二季度获得了海默尼克斯的新股份，价值约 64,000 美元。目前 99.67% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several research analysts have commented on the company. Wall Street Zen downgraded Haemonetics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 14th. Raymond James Financial reiterated an &#34;outperform&#34; rating and set a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. JPMorgan Chase &amp; Co. increased their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, December 12th. Robert W. Baird raised their target price on shares of Haemonetics from $87.00 to $99.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 15th. Finally, Mizuho upped their price target on shares of Haemonetics from $75.00 to $90.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $84.10.</p>
<div class="lb-trans"><p>几位研究分析师对该公司发表了评论。华尔街禅在 12 月 14 日的研究报告中将海默尼克斯的评级从 “买入” 下调至 “持有”。雷蒙德·詹姆斯金融公司在 11 月 14 日的研究报告中重申了 “跑赢大盘” 的评级，并设定了海默尼克斯股票的目标价为 90.00 美元。摩根大通在 12 月 12 日的研究报告中将海默尼克斯的目标价从 62.00 美元提高至 74.00 美元，并给予该公司 “中性” 评级。罗伯特·W·贝尔德在 12 月 15 日的研究报告中将海默尼克斯的目标价从 87.00 美元提高至 99.00 美元，并给予该公司 “跑赢大盘” 评级。最后，瑞穗在 12 月 17 日的报告中将海默尼克斯的目标价从 75.00 美元提高至 90.00 美元，并给予该股票 “跑赢大盘” 评级。两位分析师对该股票给予了强烈买入评级，七位给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价为 84.10 美元。</p>
</div><p><strong>Get Our Latest Analysis on Haemonetics</strong></p>
<div class="lb-trans"><p><strong>获取我们对海默尼克斯的最新分析</strong></p>
</div><h2>Haemonetics Stock Down 0.4%</h2>
<div class="lb-trans"><h2>海默尼克斯股票下跌 0.4%</h2>
</div><p>Shares of NYSE HAE opened at $80.01 on Friday. The company has a 50 day simple moving average of $70.87 and a 200 day simple moving average of $65.16. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The firm has a market cap of $3.75 billion, a PE ratio of 23.39, a price-to-earnings-growth ratio of 1.51 and a beta of 0.30.</p>
<div class="lb-trans"><p>海默尼克斯（NYSE:HAE）股票在周五开盘时为 80.01 美元。该公司的 50 日简单移动平均线为 70.87 美元，200 日简单移动平均线为 65.16 美元。该公司的债务与股本比率为 1.08，流动比率为 1.64，速动比率为 1.03。海默尼克斯公司的 1 年最低价为 47.31 美元，1 年最高价为 87.32 美元。该公司的市值为 37.5 亿美元，市盈率为 23.39，市盈率增长比率为 1.51，贝塔值为 0.30。</p>
</div><p>Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $327.32 million during the quarter, compared to analysts' expectations of $311.61 million. During the same period in the prior year, the company posted $1.12 EPS. The company's revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current year.</p>
<div class="lb-trans"><p>海默尼克斯（NYSE:HAE - 获取免费报告）最近在 11 月 6 日宣布了其季度财报。这家医疗仪器供应商报告本季度每股收益（EPS）为 1.27 美元，超出市场共识预期的 1.12 美元，超出 0.15 美元。海默尼克斯的净利润率为 12.67%，股本回报率为 27.22%。该公司在本季度的收入为 3.2732 亿美元，而分析师预期为 3.1161 亿美元。在去年同期，该公司的每股收益为 1.12 美元。该公司的收入同比下降了 5.3%。海默尼克斯已将其 2026 财年的指导目标设定为 4.800-5.00 每股收益。研究分析师平均预测海默尼克斯公司本年度将发布 4.55 每股收益。</p>
</div><h2>Haemonetics Profile</h2>
<div class="lb-trans"><h2>海默尼克斯公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.</p>
<div class="lb-trans"><p>海默尼克斯公司是一家全球血液管理解决方案提供商，支持血液及血液制品的收集、处理和输血。该公司的产品旨在提高血液中心、医院和血浆收集设施的患者安全性和运营效率。海默尼克斯通过提供集成系统、软件和消耗品，满足全球医疗服务提供者在血液管理全过程中的关键需求。</p>
</div><p>The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.</p>
<div class="lb-trans"><p>该公司的产品组合包括自动化血液成分分离和血浆收集系统、外科血液回收和凝血监测设备，以及病原体去除技术。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Haemonetics</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比海默尼克斯更好</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备开战</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
<li>来自奇怪新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HAE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 HAE 股票吗？</strong> 访问 HoldingsChannel.com 获取海默尼克斯公司（NYSE:HAE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HAE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在海默尼克斯吗？</h2>
</div><p>Before you consider Haemonetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑海默尼克斯之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Haemonetics 并不在名单上。</p>
</div><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Haemonetics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Harbor Capital Advisors Inc. 购入了 14,226 股 Heamonetics 公司的股票 $HAE